PL2606068T3 - SKOJARZONE ZASTOSOWANIE PRZECIWCIAŁ SPECYFICZNYCH WZGLĘDEM GAMMA RIIB (CD32B) I CD19, CD20 lub CD40 - Google Patents

SKOJARZONE ZASTOSOWANIE PRZECIWCIAŁ SPECYFICZNYCH WZGLĘDEM GAMMA RIIB (CD32B) I CD19, CD20 lub CD40

Info

Publication number
PL2606068T3
PL2606068T3 PL11760819T PL11760819T PL2606068T3 PL 2606068 T3 PL2606068 T3 PL 2606068T3 PL 11760819 T PL11760819 T PL 11760819T PL 11760819 T PL11760819 T PL 11760819T PL 2606068 T3 PL2606068 T3 PL 2606068T3
Authority
PL
Poland
Prior art keywords
cd32b
specific antibodies
combined use
gamma riib
riib
Prior art date
Application number
PL11760819T
Other languages
English (en)
Polish (pl)
Inventor
Mark Cragg
Martin Glennie
Ali Roghanian
Stephen Beers
Peter Johnson
Sean Lim
Björn Frendeus
Ingrid Teige
Original Assignee
University Of Southampton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Southampton filed Critical University Of Southampton
Publication of PL2606068T3 publication Critical patent/PL2606068T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
PL11760819T 2010-08-20 2011-08-19 SKOJARZONE ZASTOSOWANIE PRZECIWCIAŁ SPECYFICZNYCH WZGLĘDEM GAMMA RIIB (CD32B) I CD19, CD20 lub CD40 PL2606068T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1013989.7A GB201013989D0 (en) 2010-08-20 2010-08-20 Biological materials and methods of using the same
EP11760819.0A EP2606068B1 (en) 2010-08-20 2011-08-19 COMBINED USE OF FC GAMMA RIIB (CD32B) AND CD19-, CD20- or CD40- SPECIFIC ANTIBODIES
PCT/GB2011/051572 WO2012022985A1 (en) 2010-08-20 2011-08-19 Combined use of fc gamma riib (cd32b) and cd20 - specific antibodies

Publications (1)

Publication Number Publication Date
PL2606068T3 true PL2606068T3 (pl) 2018-03-30

Family

ID=42984443

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11760819T PL2606068T3 (pl) 2010-08-20 2011-08-19 SKOJARZONE ZASTOSOWANIE PRZECIWCIAŁ SPECYFICZNYCH WZGLĘDEM GAMMA RIIB (CD32B) I CD19, CD20 lub CD40

Country Status (17)

Country Link
US (4) US10525129B2 (enExample)
EP (2) EP2606068B1 (enExample)
JP (2) JP6215704B2 (enExample)
KR (1) KR101948609B1 (enExample)
CN (7) CN114099666B (enExample)
AU (1) AU2011290503B2 (enExample)
CA (1) CA2808744C (enExample)
DK (1) DK2606068T3 (enExample)
ES (1) ES2653685T3 (enExample)
GB (1) GB201013989D0 (enExample)
HU (1) HUE037478T2 (enExample)
NO (1) NO2606068T3 (enExample)
PL (1) PL2606068T3 (enExample)
PT (1) PT2606068T (enExample)
RU (2) RU2769949C2 (enExample)
SI (1) SI2606068T1 (enExample)
WO (1) WO2012022985A1 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201013989D0 (en) 2010-08-20 2010-10-06 Univ Southampton Biological materials and methods of using the same
RU2015125349A (ru) * 2012-11-29 2017-01-10 Байер Хелскеа Ллк МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА ПРОТИВ АКТИВИРОВАННОГО БЕЛКА С (аРС)
EP3524691A1 (en) * 2012-12-07 2019-08-14 SuppreMol GmbH Stratification and treatment of patients of idiopathic thrombocytopenic purpura
PL2970487T3 (pl) 2013-03-12 2020-09-21 Molecular Templates, Inc. Białka cytotoksyczne zawierające regiony wiążące ukierunkowane na komórkę oraz regiony podjednostki a toksyny shiga do selektywnego zabijania specyficznych typów komórek
EP2833139A1 (en) * 2013-08-01 2015-02-04 SuppreMol GmbH In vitro method for determining the stability of compositions comprising soluble Fc gamma receptor(s)
CN112851769A (zh) 2014-01-27 2021-05-28 分子模板公司 用于哺乳动物中的去免疫化志贺毒素a亚基效应子多肽
US11142584B2 (en) 2014-03-11 2021-10-12 Molecular Templates, Inc. CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same
GB2526139A (en) * 2014-05-15 2015-11-18 Biolnvent Internat Ab Medicaments, uses and methods
AU2015274647C1 (en) 2014-06-11 2020-01-30 Molecular Templates, Inc. Protease-cleavage resistant, Shiga toxin a subunit effector polypeptides and cell-targeted molecules comprising the same
KR20170110601A (ko) 2015-02-05 2017-10-11 몰레큘러 템플레이츠, 인코퍼레이션. 시가 독소 a 서브유닛 작동체 영역을 포함하는 다가 cd20 결합 분자 및 이들의 강화된 조성물
RU2733496C2 (ru) * 2015-03-16 2020-10-02 Гельмгольц Центрум Мюнхен - Дойчес Форшунгсцентрум Фюр Гезундхайт Унд Умвельт (Гмбх) Триспецифические связывающие молекулы для лечения вирусной инфекции гепатита в и связанных состояний
EP3303373B1 (en) 2015-05-30 2020-04-08 Molecular Templates, Inc. De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
AU2016370813A1 (en) 2015-12-18 2018-06-28 Novartis Ag Antibodies targeting CD32b and methods of use thereof
KR102580647B1 (ko) 2016-12-07 2023-09-20 몰레큘러 템플레이츠, 인코퍼레이션. 부위 특이적 접합을 위한 시가 독소 a 서브유닛 작동체 폴리펩타이드, 시가 독소 작동체 스캐폴드, 및 세포-표적화 분자
EP3551034A1 (en) 2016-12-07 2019-10-16 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
KR102590672B1 (ko) 2017-01-25 2023-10-18 몰레큘러 템플레이츠, 인코퍼레이션. 탈면역된 시가 독소 a 서브유닛 이펙터 및 cd8+ t-세포 에피토프를 포함하는 세포-표적화 분자
EP3573640A4 (en) * 2017-01-30 2021-04-28 The Ohio State Innovation Foundation PASSIVE ANTIBODY DEPENDENT CELLULAR MEDIATION ACTIVATION
EP3600416B1 (en) 2017-03-30 2023-06-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
WO2018229706A1 (en) 2017-06-16 2018-12-20 Novartis Ag Combination therapy for the treatment of cancer
EP3700933A1 (en) 2017-10-25 2020-09-02 Novartis AG Antibodies targeting cd32b and methods of use thereof
KR20200096253A (ko) 2017-11-30 2020-08-11 노파르티스 아게 Bcma-표적화 키메라 항원 수용체, 및 이의 용도
KR20200143634A (ko) 2018-04-17 2020-12-24 몰레큘러 템플레이츠, 인코퍼레이션. 탈면역된 시가 독소 a 서브유닛 스캐폴드를 포함하는 her2-표적화 분자
CN108823211A (zh) * 2018-05-04 2018-11-16 中国医学科学院基础医学研究所 一种cd19核酸适配体及其应用
UY38251A (es) 2018-06-01 2019-12-31 Novartis Ag Moléculas de unión contra bcma y usos de las mismas
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
WO2019246317A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease or condition in a tissue originating from the endoderm
AU2019383976B2 (en) 2018-11-19 2025-07-03 Bt Bidco, Inc. Methods and devices for treating a disease with biotherapeutics
CN114127119A (zh) * 2019-07-17 2022-03-01 生物发明国际公司 用于治疗特定患者的癌症的抗体组合
TW202122114A (zh) * 2019-10-18 2021-06-16 美商建南德克公司 使用抗CD79b 免疫偶聯物治療彌漫性大B 細胞淋巴瘤的方法
US11707610B2 (en) 2019-12-13 2023-07-25 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
EP3919077A1 (en) 2020-06-04 2021-12-08 BioInvent International AB Model for prediction of tolerability issues in connection with intravenous administration of therapeutic antibodies
IL298757A (en) * 2020-06-04 2023-02-01 Bioinvent Int Ab Improving antibody tolerability associated with intravenous administration
IL302569A (en) 2020-11-06 2023-07-01 Novartis Ag Cd19 binding molecules and uses thereof
TW202336033A (zh) 2022-03-07 2023-09-16 瑞典商生物創新國際有限公司 抗體之新穎組合及用途
US20230399375A1 (en) 2022-04-15 2023-12-14 Kyverna Therapeutics, Inc. Methods and compositions for treating autoimmune disease
US20240261405A1 (en) 2022-06-08 2024-08-08 Kyverna Therapeutics, Inc. Methods and compositions for treating autoimmune disease

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
ATE221379T1 (de) 1991-05-01 2002-08-15 Jackson H M Found Military Med Verfahren zur behandlung infektiöser respiratorischer erkrankungen
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
ATE508733T1 (de) 1996-03-04 2011-05-15 Penn State Res Found Materialien und verfahren zur steigerung der zellulären internalisierung
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
ES2236832T3 (es) 1997-01-16 2005-07-16 Massachusetts Institute Of Technology Preparacion de particulas para inhalacion.
WO1999066903A2 (en) 1998-06-24 1999-12-29 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
CA2390412A1 (en) * 1999-11-08 2001-05-17 Idec Pharmaceuticals Corporation Treatment of b cell malignancies using anti-cd40l antibodies in combination with anti-cd20 antibodies and/or chemotherapeutics and radiotherapy
AU2003262650B2 (en) * 2002-08-14 2009-10-29 Macrogenics, Inc. FcgammaRIIB-specific antibodies and methods of use thereof
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
AU2003265522A1 (en) * 2003-08-18 2005-03-10 Macrogenics, Inc. FCGammaRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
PL1709073T3 (pl) 2003-11-26 2012-01-31 Max Planck Gesellschaft Substancja wiążąca receptor IIb Fc ludzkiej IgG (FcγRIIb)
CN101001872A (zh) * 2004-04-16 2007-07-18 宏观基因有限公司 FcγRIIB－特异性抗体及其使用方法
MXPA06011796A (es) * 2004-04-16 2007-05-07 Macrogenics Inc Anticuerpos especificos de fc(riib y metodos para el uso de los mismos.
KR101297146B1 (ko) 2004-05-10 2013-08-21 마크로제닉스, 인크. 인간화 ＦｃγＲＩＩＢ 특이적 항체 및 그의 사용 방법
CA2566535A1 (en) * 2004-05-20 2006-05-11 St. Mary's Hospital Nhs Trust Ige-retargeting, function-altering molecules (erfam) for treatment of allergic diseases
WO2007024249A2 (en) 2004-11-10 2007-03-01 Macrogenics, Inc. Engineering fc antibody regions to confer effector function
CA2590935C (en) * 2004-12-15 2014-09-30 Macrogenics, Inc. Fc.gamma.riib-specific antibodies and methods of use thereof
EP1674479A1 (en) * 2004-12-22 2006-06-28 Memorial Sloan-Kettering Cancer Center Modulation of Fc Gamma receptors for optimizing immunotherapy
WO2008002933A2 (en) * 2006-06-26 2008-01-03 Macrogenics, Inc. Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
WO2008140603A2 (en) 2006-12-08 2008-11-20 Macrogenics, Inc. METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
US20120039871A1 (en) * 2007-11-08 2012-02-16 Pikamab, Inc. Methods and compositions for antibody therapy
EP2234641B1 (en) 2008-01-03 2015-08-19 Genmab A/S Monoclonal antibodies against cd32b
US20110268753A1 (en) 2009-01-08 2011-11-03 The Uab Research Foundation Process for regulating immune response
GB201013989D0 (en) * 2010-08-20 2010-10-06 Univ Southampton Biological materials and methods of using the same
GB2526139A (en) 2014-05-15 2015-11-18 Biolnvent Internat Ab Medicaments, uses and methods

Also Published As

Publication number Publication date
CN114099668B (zh) 2025-10-17
JP2013537547A (ja) 2013-10-03
CN114099667B (zh) 2025-10-21
AU2011290503B2 (en) 2015-09-03
US20130251706A1 (en) 2013-09-26
RU2017143633A3 (enExample) 2021-01-29
CN114099667A (zh) 2022-03-01
CN114099668A (zh) 2022-03-01
CA2808744A1 (en) 2012-02-23
RU2017143633A (ru) 2019-02-14
US20210346498A1 (en) 2021-11-11
KR20140005866A (ko) 2014-01-15
CN114099702A (zh) 2022-03-01
CN114099669A (zh) 2022-03-01
CN114099666A (zh) 2022-03-01
CN107670034B (zh) 2021-07-20
US10525129B2 (en) 2020-01-07
RU2769949C2 (ru) 2022-04-11
RU2013112345A (ru) 2014-09-27
KR101948609B1 (ko) 2019-02-15
US11623005B2 (en) 2023-04-11
JP2016138129A (ja) 2016-08-04
CN103080131A (zh) 2013-05-01
JP6215704B2 (ja) 2017-10-18
AU2011290503A1 (en) 2013-03-07
WO2012022985A1 (en) 2012-02-23
CN114099702B (zh) 2024-08-27
JP6421140B2 (ja) 2018-11-07
EP2606068A1 (en) 2013-06-26
SI2606068T1 (en) 2018-01-31
US20200069798A1 (en) 2020-03-05
GB201013989D0 (en) 2010-10-06
HUE037478T2 (hu) 2018-08-28
CN107670034A (zh) 2018-02-09
DK2606068T3 (da) 2017-11-20
PT2606068T (pt) 2017-12-29
NO2606068T3 (enExample) 2018-02-24
ES2653685T3 (es) 2018-02-08
US20230381310A1 (en) 2023-11-30
CA2808744C (en) 2023-03-07
EP2606068B1 (en) 2017-09-27
EP3263602A1 (en) 2018-01-03
CN114099666B (zh) 2025-05-02

Similar Documents

Publication Publication Date Title
PL2606068T3 (pl) SKOJARZONE ZASTOSOWANIE PRZECIWCIAŁ SPECYFICZNYCH WZGLĘDEM GAMMA RIIB (CD32B) I CD19, CD20 lub CD40
LTPA2017041I1 (lt) Anti-PD-L1 antikūnai ir jų panaudojimas T ląstelių funkcijos pagerinimui
IL250691B (en) Anti-ox40 antibodies and methods of using them
PT2424896E (pt) Anticorpos anti-ceacam1 e métodos de utilização dos mesmos
IL237737B (en) Human monoclonal antibodies against pd-l1 and methods of use
ZA201304654B (en) Systems and methods to assess cognitive function
EP2599217A4 (en) Gfsk receiver architecture and methodology
EP2539005A4 (en) ORAL PIECE AND METHODS OF USING THE SAME
EP2654549A4 (en) INTEGRATED SYSTEM ARCHITECTURES AND USE PROCESSES
ZA201304153B (en) Anti-pcsk9 antibodies and methods of use
PL2621955T3 (pl) Przeciwciała anty-CEACAM6 i ich zastosowania
EP2734234A4 (en) ANTI-CXCR4 ANTIBODIES AND METHOD OF USE THEREOF
ZA201401326B (en) Novel anti-cxcr4 antibody and its use for the detection and diagnosis of cancer
IL225389A0 (en) Antibody preparations and methods of use
ZA201300174B (en) Anti-neuropilin antibodies and methods of use
IL230693A0 (en) Use of the i-3859 antibody for the detection and diagnosis of cancer
ZA201205271B (en) Predicting and reducing alloimmunogenicity of protein therapeutics
EP2875347A4 (en) METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND PROGNOSIS OF SEPSIS
GB201010942D0 (en) Display of input selection
EP2553151A4 (en) USE OF INDUCED PLURIPOTENTIAL CELLS AND OTHER CELLS FOR SCREENING COMPOSITE LIBRARIES
HK40066736B (zh) FCγRIIB(CD32B)和CD20特异性抗体的组合应用
HK40066736A (zh) FCγRIIB(CD32B)和CD20特异性抗体的组合应用
HK40066733A (zh) FCγRIIB(CD32B)和CD20特异性抗体的组合应用
HK40066734A (zh) FCγRIIB(CD32B)和CD20特异性抗体的组合应用
HK40066735A (zh) FCγRIIB(CD32B)和CD20特异性抗体的组合应用